Grating Visual Acuity Results in the Early Treatment for Retinopathy of Prematurity Study

Wv, Good; Rj, Hardy; Ea, Palmer; Dl, Phelps; Tung, Betty; Redford, Maryann

doi:10.1001/archophthalmol.2011.143

Cited by 75 publications

(10 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Much of our knowledge about outcomes in children with retinopathy of prematurity comes from the CRYO-ROP 132,133,144–146 and ETROP 117,135,147,148 studies. Severe retinopathy of prematurity often leads to long-term visual loss, with blindness in the most severe cases.…”

Section: Long-term Outcomesmentioning

confidence: 99%

See 1 more Smart Citation

Retinopathy of prematurity

2013

View full text Add to dashboard Cite

The immature retinas of preterm neonates are susceptible to insults that disrupt neurovascular growth, leading to retinopathy of prematurity. Suppression of growth factors due to hyperoxia and loss of the maternal–fetal interaction result in an arrest of retinal vascularisation (phase 1). Subsequently, the increasingly metabolically active, yet poorly vascularised, retina becomes hypoxic, stimulating growth factor-induced vasoproliferation (phase 2), which can cause retinal detachment. In very premature infants, controlled oxygen administration reduces but does not eliminate retinopathy of prematurity. Identification and control of factors that contribute to development of retinopathy of prematurity is essential to prevent progression to severe sight-threatening disease and to limit comorbidities with which the disease shares modifiable risk factors. Strategies to prevent retinopathy of prematurity will depend on optimisation of oxygen saturation, nutrition, and normalisation of concentrations of essential factors such as insulin-like growth factor 1 and ω-3 polyunsaturated fatty acids, as well as curbing of the effects of infection and inflammation to promote normal growth and limit suppression of neurovascular development.

show abstract

Section: Long-term Outcomesmentioning

confidence: 99%

“…A subgroup analysis suggested a benefit from earlier (before threshold) compared with later (at threshold) treatment in more severe cases (type 1 disease; 16% vs 25%; p=0·004), but not in milder cases (type 2 disease; 21% vs 16%; p=0·29). 147 …”

Section: Long-term Outcomesmentioning

confidence: 99%

Retinopathy of prematurity

2013

View full text Add to dashboard Cite

show abstract

“…1–4 Although ablative therapy has been shown in a multicenter randomized trial to improve structural and functional outcomes, it also destroys retinal tissue, and some treated infants have poor visual outcomes. 5,6 Antivascular endothelial growth factor (VEGF) agents have been proposed as a less destructive treatment alternative. In the Bevacizimab Eliminates the Angiogenic Threat of Retinopathy of Prematurity (BEAT-ROP) trial, the first multicenter randomized trial of an anti-VEGF agent for ROP, intravitreal bevacizumab, compared to laser therapy, reduced the rate of recurrence of zone I ROP 7,8 and decreased myopia and high myopia.…”

mentioning

confidence: 99%

Medical and developmental outcomes of bevacizumab versus laser for retinopathy of prematurity

Kennedy

Mintz-Hittner

2018

Journal of American Association for Pediatric Ophthalmology and

View full text Add to dashboard Cite

show abstract

“…Acuity deficits in ROP patients are common, even if the ROP had been successfully treated or was mild and, by clinical criteria, resolved completely. Most of the 15-year alumni of the CRYO-ROP study45 and two-thirds of the 6-year alumni of the ETROP study46 had acuity poorer than 20/40.…”

Section: Central Retina In Ropmentioning

confidence: 91%

Retinal, visual, and refractive development in retinopathy of prematurity

Moskowitz¹,

Hansen²,

Fulton³

2016

View full text Add to dashboard Cite

The pivotal role of the neurosensory retina in retinopathy of prematurity (ROP) disease processes has been amply demonstrated in rat models. We have hypothesized that analogous cellular processes are operative in human ROP and have evaluated these presumptions in a series on non-invasive investigations of the photoreceptor and post-receptor peripheral and central retina in infants and children. Key results are slowed kinetics of phototransduction and deficits in photoreceptor sensitivity that persist years after ROP has completely resolved based on clinical criteria. On the other hand, deficits in post-receptor sensitivity are present in infancy regardless of the severity of the ROP but are not present in older children if the ROP was so mild that it never required treatment and resolved without a clinical trace. Accompanying the persistent deficits in photoreceptor sensitivity, there is increased receptive field size and thickening of the post-receptor retinal laminae in the peripheral retina of ROP subjects. In the late maturing central retina, which mediates visual acuity, attenuation of multifocal electroretinogram activity in the post-receptor retina led us to the discovery of a shallow foveal pit and significant thickening of the post-receptor retinal laminae in the macular region; this is most likely due to failure of the normal centrifugal movement of the post-receptor cells during foveal development. As for refractive development, myopia, at times high, is more common in ROP subjects than in control subjects, in accord with refractive findings in other populations of former preterms. This information about the neurosensory retina enhances understanding of vision in patients with a history of ROP, and taken as a whole, raises the possibility that the neurosensory retina is a target for therapeutic intervention.

show abstract

Grating Visual Acuity Results in the Early Treatment for Retinopathy of Prematurity Study

Cited by 75 publications

References 22 publications

Retinopathy of prematurity

Retinopathy of prematurity

Medical and developmental outcomes of bevacizumab versus laser for retinopathy of prematurity

Retinal, visual, and refractive development in retinopathy of prematurity

Contact Info

Product

Resources

About